Literature DB >> 12675170

Health and socioeconomic status differences among antibody hepatitis C positive and negative transfusion recipients, 1986-1990.

Robert S Hogg1, Kevin J P Craib, David Pi, Samuel S Lee, Gerald Y Minuk, Colin M Shapiro, Martin T Schechter, Michael V O'Shaughnessy.   

Abstract

OBJECTIVE: To characterize the socioeconomic and health status, disease symptoms of anti-HCV-positive and negative transfusion recipients.
METHODS: A cross-sectional interviewer-administered survey of subjects identified through the British Columbia Blood Recipient Program. Study subjects were 18 years and over and had to have had a transfusion between August 1, 1986 and June 30, 1990 and completed an interview of satisfactory quality. Anti-HCV-positive subjects were those seeking monetary compensation from the provincial and Canadian governments and the comparison group was randomly selected from a pool of anti-HCV-negative subjects. The study was designed to detect an assumed difference of 20% in signs and symptoms between the two groups. Statistical comparisons were conducted using bivariate and multivariate logistic regression analyses.
RESULTS: A total of 241 and 222 anti-HCV-positive and negative subjects were respectively interviewed and met the study's eligibility criteria. Results from the multivariate analysis indicated that anti-HCV-positive recipients were more likely to have two or more clinical symptoms (OR = 3.53; 95% CI: 1.44, 8.70), to be in worse health status as compared to ten years previous (OR = 1.60; 95% CI: 1.30, 1.96), to have a higher illness intrusiveness rating (OR = 1.35; 95% CI: 1.25, 1.46), and to be younger (OR = 0.97; 95% CI: 0.95, 0.98).
CONCLUSION: Our results show that persons exposed to HCV were more likely to have had two or more clinical symptoms, be male, have worse health status as compared to ten years previous, have a higher illness intrusiveness rating, and be younger in age.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675170      PMCID: PMC6979785     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  10 in total

1.  Correlates of daytime sleepiness in 4578 elderly persons: the Cardiovascular Health Study.

Authors:  C W Whitney; P L Enright; A B Newman; W Bonekat; D Foley; S F Quan
Journal:  Sleep       Date:  1998       Impact factor: 5.849

2.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

Authors:  E Kenny-Walsh
Journal:  N Engl J Med       Date:  1999-04-22       Impact factor: 91.245

3.  The impact of diagnosis of hepatitis C virus on quality of life.

Authors:  A J Rodger; D Jolley; S C Thompson; A Lanigan; N Crofts
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

4.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

Authors:  L B Krupp; N G LaRocca; J Muir-Nash; A D Steinberg
Journal:  Arch Neurol       Date:  1989-10

5.  Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.

Authors:  G R Foster; R D Goldin; H C Thomas
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

6.  Sleepiness in different situations measured by the Epworth Sleepiness Scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1994-12       Impact factor: 5.849

7.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

8.  Quality of life and lifestyle disruption in euthymic bipolar disorder.

Authors:  J C Robb; R G Cooke; G M Devins; L T Young; R T Joffe
Journal:  J Psychiatr Res       Date:  1997 Sep-Oct       Impact factor: 4.791

9.  Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale.

Authors:  M W Johns
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

10.  Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  Clin Ther       Date:  1994 Mar-Apr       Impact factor: 3.393

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.